3Sharms S K,Balamurugan A,Saha P K,et al.Evaluation of clinical and immunogenetic risk factors for the development of hepatotoxicity during antituberculosis treatment[J].Am J Respir Crit Care Med,2002,166(7):916 -919.
4Teleman M D,Chee C B E,Earnest A,et al.Hepatotoxicity of tuberculosis chemotherapy under general programme conditions in Singapore[J].Iht Tuberc Lung Dis,2002,6 (8):699-705.
5American Thoracic Society/Centers For Disease Control and Prevention (ATS/CDC).Executive Committee,Update:Fatal and Severe Liver Injuries Associated With Rifampin and Pyrazinamide for Latent Tuberculosis Infection,and Revisions in American Thoracic Society/CDC Recommendations-United States,2001[J].Am J Respir Crit Care Med,2006,169(7):1319 -1320.
6Nolan C M,Goldberg S V,Buskin S E.Hepatotoxicity associated with isoniazid prevention therapy[J].JAMA,2006,288:1014-1018.
7Ungo J R,Jones D A,shkin D,et al.Antituberculosis drug-induced hepatotoxicity the role of hepatitis C virus and the human immunodeficienc,virus[J].Am J Respir Cril Care Med,2006,165(7):1871-1876.
8Wang W M,Wu P C,Yuen M F,et al.Antituberculosis drug-related liver dysfunction in chronic hepatitis B infection[J].Hepatology,2000,31:201-206.
